Vivesto — Board/Management Information 2013

Sep 11, 2013

2013-09-11

PRESS RELEASE

Oasmia€s two major shareholders nominate Alexander Kotsinas to new board member

In connection with Oasmia€s annual general meeting on September 30, the company€s two major shareholdersAlceco International S.A.and Nexttobe ABhave put forward a proposition to expand the board of Oasmia with Alexander Kotsinas, today part of the management team of Nexttobe.

€Ever since Nexttobe became a shareholder of Oasmia, there have been discussions with the largest shareholderAlceco to strengthen the board with one more member. Alexander•s long -time experience from the business community, and especially the life science sector, makes him a valuable addition', commented Julian Aleksov, CEO of Oasmia.

Prior to joiningNexttobe,AlexanderKotsinasserved as Vice President and CFO of Q -Med AB. Previously, he held positions at Life Europe, 3 Scandinavia, Investorand Ericsson. Alexander has a Master of Science from the Royal Institute of Technology in Applied Physics and a Bachelor of Science from Handelshƒgskolan in Stockholm.

About Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company•s product development aims to create and manufacture nov el nanoparticle formulations and drug-delivery systems based on well -established cytostatics which, in comparison with current alternatives, show improved properties, reduced side -effects, and expanded applications. The company•s product development is bas ed on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).

For more information, please contact: Mikael Widell , Vice President Communications , Oasmia Pharmaceutical AB. E -mail: Mikael.widell@oasmia.com Mobile: +46 (0) 703 11 99 60. Information is also available at www.oasmia.com www.nasdaqomxnordic.com www.boerse -frankfurt.de twitter.com/oasmia

€Oasmia is requiredunder the Financial Instruments Trading Act to make the information in this press release public. The information was submittedfor publicationat 09.30, CET onSeptember 11, 2013.•